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FoxP3Abstract Aim of the work: Persistent inﬂammation and recurring activity in rheumatoid arthritis
(RA) daring a quarterback of T regulatory cells (Tregs) intrigued rheumatologists. Tregs’ most spe-
ciﬁc marker is the forkhead box P3 (FoxP3) denoting FoxP3+ cells as suppressors whereas FoxP3
as effectors. This study evaluates subset distribution of peripheral blood (PB) CD4+CD25+ Tregs
according to FoxP3 expression in RA to better understand its role in pathogenesis.
Patients and methods: In our observational cross-sectional study PB Tregs from 40 RA patients
and 20 age and sex matched healthy controls (HC) were characterized and quantiﬁed by ﬂow
cytometry. Disease activity was evaluated by DAS28. Patients were divided into: active RA group
(ARA) and remission RA group (RRA).
Results: Signiﬁcantly higher CD4+CD25+FoxP3+ Tregs were found on comparing RRA, ARA
patients and HC (mean 153.25 ± 6.29, 136.3 ± 3.27 and 97.25 ± 6.25, respectively) with a statis-
tically highly signiﬁcant difference (F= 553.13, p< 0.001). CD4+CD25+FoxP3 increased 3-
folds in RRA and 4-folds in ARA compared to HC and CD4+CD25+FoxP3+ increased 1.6-folds
in RRA and 1.5-folds in ARA. Thus the ratio of FoxP3/FoxP3+ cells is altered from 1:3 in HC to
186 N. Abaza et al.2:3 in RRA and 1:1 in ARA. CD4+CD25+FoxP3+ had a highly signiﬁcant negative correlation
with disease activity score DAS28 (r= 0.86, p< 0.001).
Conclusion: Though CD4+CD25+FoxP3+ and CD4+CD25+FoxP3 are both increased in
RA, their balance is more important; abundant FoxP3 cells with effector function have the upper
hand over suppressive FoxP3+ cells. This imbalance relates to RA presence and activity. Reinforc-
ing FoxP3 expression might be a good potential therapeutic target in RA.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
The regulatory T cells (Tregs) CD4+CD25+ which speciﬁcally
express the forkhead family transcription factor (FoxP3) are
essential for the maintenance of immunological self-tolerance
and homeostasis. Tregs suppress the activation, prolifera-
tion and effector function of other lymphocytes in physiologi-
cal and pathological immune responses. Therefore, control of
the development, survival, and function of Tregs is instrumen-
tal for effective controlled immune responses [1].
FoxP3 is speciﬁcally expressed in CD4+CD25+ Tregs
which is crucial for their development and is needed to main-
tain the suppressive function of the mature peripheral Tregs
[2]. Decreased FoxP3 expression causes immune disease by
subverting the suppressive function of Tregs and converting
them into effector cells [3].
Tregs have a central role in protecting an individual from
autoimmunity. This role was ﬁrst identiﬁed in mice in which
the absence or depletion of these cells resulted in the develop-
ment of autoimmune disorders [4,5].
Rheumatoid arthritis (RA) is a common chronic autoim-
mune inﬂammatory disease characterized by destruction of
the synovial joints, leading to progressive disability, increased
co-morbidity and premature mortality [6,7]. The genetic pre-
disposition to RA is dominated by the major histocompatibil-
ity complex HLA-DR and because the function of HLA-DR is
to present peptides to CD4+ T cells, a role for antigen-acti-
vated T cells in at least the initiation of RA is implied [8].
Data regarding the number of circulating Tregs in RA pa-
tients compared to healthy individuals are inconclusive and
contradictory. Some studies showed a decrease of circulating
Tregs in RA patients compared to healthy individuals [9]
whereas others showed no difference [10] and some indicated
an increase [11]. While accumulating evidences support that
CD4+CD25+ Tregs play an essential role in controlling and
preventing autoimmunity [12], several reports have described
increased numbers of CD4+CD25high T cells also in the syno-
vial ﬂuid of RA patients [11,13]. Interestingly, many studies
have reached the seemingly paradoxical conclusion that auto-
immune arthritis can develop despite the presence of
CD4+CD25+ Tregs. These observations raise the question
of whether these cells in arthritic patients are perhaps dysfunc-
tional, or functional but unable to prevent disease, or are mod-
ifying it in some manner [14].
Tregs’ role in other rheumatic diseases such as systemic lupus
erythematosus (SLE) is suggested. Characterization of circulat-
ing Tregs in SLE patients has been analyzed based on expression
of intracellular FoxP3 transcription factor [15]. Some reports
have shown a decrease of CD4+CD25+FoxP3+ Tregs in SLE
patients compared to healthy individuals with inverse correla-
tion with activity [16,17] and without this correlation [18].However, other studies revealed normal levels [19–21]. Other re-
ports showed an increase of circulating CD4+CD25+FoxP3+
Tregs that correlates with disease activity [22–24].
Hence, CD4+CD25+ Tregs can play a critical role in the
prevention of autoimmunity. At present, however, how and
whether they participate in the development of RA remains
unclear [14].
In this study, we aimed at clarifying the subset distribution
of CD4+CD25+ Tregs according to FoxP3 (whether a lack of
suppressors FoxP3+ or excess of effectors FoxP3) in RA
(both in remission and activity) for a better understanding of
rheumatoid arthritis pathogenesis.
2. Patients and methods
The present study is an observational cross-sectional one that
included 40 patients with RA fulﬁlling the new EULAR/ACR
criteria of 2010 [25]. Twenty age and sex matched healthy sub-
jects were also included in the study and served as control
group. All patients were seropositive for rheumatoid factor
(RF) and/or anticitrullinated protein (AntiCCP) antibodies.
All the patients were on methotrexate (MTX) and folic acid.
Written consent was obtained from all patients and controls
after a full explanation of the study which was approved by
the local ethics committee.
2.1. Exclusion criteria
Patients with acute infection, other autoimmune disorders or
those receiving any other disease-(modifying antirheumatic
drug(s)) DMARDS other than MTX were excluded from the
study.
2.2. Clinical assessment
- Full history taking including disease duration and drug
intake.
- Thorough clinical assessment of the patients which included
the following:
*Disease activity was evaluated using 28 tender and swollen
joint count disease activity score (DAS28) [26] [high disease
activity >5.1, moderate disease activity <5.1 and >3.2, low
disease activity <3.2, remission <2.6]. Patients were divided
into two groups: (1) those with active RA (ARA group)
(n= 20) (2) those whose disease was in clinical remission
(RRA group) (n= 20). We intended to recruit equal number
of patients in each group. All patients in the group with active
RA and the remission group were on stable therapy MTX and
folic acid.
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- Complete blood count (Cell Dyne-2700, Abott Lab., USA).
- Erythrocyte sedimentation rate (ESR) using Westergren
method.
- CRP by latex agglutination using AVITEX CRP supplied
by Omega Diagnostics Ltd.
- Detection of anti CCP antibodies: serum anti CCP levels
were assessed by an ELISA methodology using QUANTA
Lite TM CCP3 IgG semiquantitative ELISA kit, INOVA
Diagnostics, San Diego, CA USA.
- RF was detected by the kit supplied by Biotec Laboratories
based on agglutination test using particles sensitized with
human IgG.
- Liver function tests and kidney function tests using Syn-
chron CX9 (Beckman instrument Inc. Brea, California,
USA).
- Flow cytometry.
Two milliliters of the peripheral venous blood was collected
from each subject using vacutainer containing anticoagulant
potassium ethylene diamine tetra acetate (EDTA) in a ﬁnal
concentration of 1.5 mg/ml.
Fifty microliters of whole anticoagulated blood was
lysed using 1 ml IQ test lysing reagent (Beckman coulter,
Miami, USA) followed by washing with phosphate buffer
saline (PBS) (Oxoid, Hampshire, UK). After that, the cells
were stained with combinations of the following antibodies
(5 ul each): anti-CD-25-PE, anti-CD4-FITC and isotypes
controls (FITC and PE) (Beckman, Coulter). The test
tubes were then incubated in the dark for 20 min followed
by washing with PBS. Intracellular staining FoxP3-PE-Cy5
(eBioscience, California, USA) was as follows: anticoagu-
lated whole blood was ﬁxed and permeabilized using
FoxP3 staining buffer set (eBioscience) according to the
manufacturer’s instructions with certain modiﬁcations in
brief.
After washing, the cell pellet was resuspended in 0.5 ml of
freshly prepared ﬁxation/permeabilization working solution
and incubated for 30 min at 4 C in the dark. This was fol-
lowed by washing once with PBS followed by washing once
again with 1 ml of 1· permeabilization buffer. Ten microlitersTable 1 Clinical and laboratory data of the RA patients.
RA patient groups
ARA group R
Mean ± SD M
Disease duration (years) 6.80 ± 4.59 5
DAS28 5.18 ± 0.95 1
TJC 7.00 ± 3.21 0
SJC 2.75 ± 0.96 0
ESR (mm/hour) 51.75 ± 18.66 9
CRP (mg/dl) 24.00 ± 9.76 4
PGH 4.25 ± 1.77 0
MTX (mg/week) 17.25 ± 2.91 13
ARA= active rheumatoid arthritis, RRA= remission rheumatoid ar
SJC = swollen joint count, ESR= erythrocyte sedimentation rat
MTX=methotrexate.of FoxP3-PE-Cy5 was added and incubated for 30 min at 4 C
in the dark. Lastly washing with PBS followed by resuspension
in PBS for analysis was done.
Data acquisition and analysis were performed on EP-ICS
XL ﬂow cytometry using SYSTEM II version three software
with a standard three color ﬁlter conﬁguration.
Lymphocytes were gated via their forward and side scatter
light properties. Dot blot was set as FL1 and Fl2 markers
which represent CD4+(FITC) and CD25+(PE), respectively.
T regulatory lymphocytes were identiﬁed as cells double posi-
tive for FITC and PE ﬂuorescence.
The statistical analysis was performed by IBM SPSS statis-
tics (V. 19.0, IBM Corp., USA, 2010) used for data analysis.
Data were expressed as Mean ± SD for quantitative measures.
The following tests were done:
1. Comparison of two independent mean groups for paramet-
ric data using Student’s t test.
2. Comparison between two independent groups for non-
parametric data using Wilcoxon Rank Sum test (Mann–
Whitney–Wilcoxon test).
3. Comparison between three independent groups for paramet-
ric data using analysis of variance (ANOVA) and further by
analysis of covariance (ANCOVA) and Tukey’s test.
4. Ranked Spearman correlation test to study the possible
association between each two variables among each group.
Also partial correlation was performed to measure the
degree of association between two variables, with the effect
of a controlling variable removed.3. Results
3.1. Clinical and laboratory data of RA patients
This study included 40 patients with RA, 20 in the activity
ARA group (18 females and 2 males), 20 in the remission
RRA group (17 females and 3 males) and 20 in the healthy
control (HC) group (17 females and 3 males); their ages ranged
from 29 to 56 years in the ARA group (mean 43.50 ± 6.86),
from 28 to 55 years in the RRA group (mean 41.30 ± 7.81)
and from 27 to 55 years in the HC group (meanT-test or Mann–Whitney^
RA group T or Z^ p value
ean ± SD
.40 ± 3.22 1.107 0.275
.87 ± 0.52 13.598 <0.001*
.35 ± 0.48 5.525^ <0.001*
.20 ± 0.41 5.489^ <0.001*
.65 ± 2.70 9.981 <0.001*
.40 ± 1.31 8.896 <0.001*
.45 ± 0.64 5.367^ <0.001*
.37 ± 1.22 5.48 <0.001*
thritis, DAS = disease activity score, TJC = tender joint count,
e, CRP= C reactive protein, PGH= patient global health,
188 N. Abaza et al.41.15 ± 7.82). There was no signiﬁcant difference between the
three groups as regards age or sex.
The disease duration ranged from 3 to 18 years in the ARA
group (mean 6.80 ± 4.59) and from 2 to 15 years in the RRA
group (mean 5.40 ± 3.29) with no signiﬁcant difference be-
tween the two groups (t= 1.107, p= 0.275). Patients were
on MTX ranging from 12.5–25 mg/week (mean 17.25 ± 2.9
in ARA group and 13.37 ± 1.22 in RRA group) as well as
one tablet of folic acid (5 mg) only on the following day.
Evaluation of disease activity by DAS28 in the ARA group
ranged from 3.01 to 6.41 (mean 5.18 ± 0.95) and in the RRA
group from 0.97 to 2.58 (mean 1.87 ± 0.52). The active group
had a higher ESR, CRP, tender joint count (TJC), swollen
joint count (SJC) and patient global health (PGH) values com-
pared to those of the inactive group (Table 1).0
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Figure 1 Comparison between the three studied groups as
regards CD4+CD25+, CD4+CD25+FoxP3+ and
CD4+CD25+FoxP3 T cell levels (cell number/ll blood).
ARA= active rheumatoid arthritis, RRA= remission rheuma-
toid arthritis.3.2. Comparison between T regulatory cells in RA patients and
healthy controls
Comparison between patients and controls as regards T regula-
tory cells showed that there was a statistically highly signiﬁcant
difference (p< 0.001) as regardsCD4+Tcells, CD4+CD25+T
cells as well as CD4+CD25+FoxP3+ and CD4+CD25+
FoxP3 subsets (in terms of cell number/ll blood) being all in-
creased in patients (Table 2) and (Figs. 1–3). Also an increase
of statistically highly signiﬁcant difference (p< 0.001) found
in the relative percentage of CD4+CD25+FoxP3+ out of the
CD4+CD25+ T cell population was observed in patients (Ta-
ble 2). Further, on performing the Tukey’s test after ANOVA
test there was also a statistically highly signiﬁcant difference be-
tween each two groups of the three groups (p< 0.001) in all
studied T cell subsets. The T cells were higher in patients in com-
parison to controls and higher in ARA in comparison to RRA
except CD4+CD25+FoxP3+ that was higher in RRA than inTable 2 Comparison between RA patients and control as regards
Cell population
(cell number/ll blood)
Group
CD4+ ARA
RRA
Control
CD4+CD25+ ARA
RRA
Control
CD4+CD25+/CD4 ARA
RRA
Control
CD4+CD25+FoxP3+ ARA
RRA
Control
CD4+CD25+FoxP3 ARA
RRA
Control
Relative % ARA
RRA
Control
ARA= active rheumatoid arthritis, RRA= remission rheumatoid ar
CD4+CD25+FoxP3+ out of CD4+CD25+ T cells.the ARA group. Putting MTX as a covariant and performing
analysis of covariant ANCOVA test to eliminate its effect on
the difference between the RA groups as regards
CD4+CD25+FoxP3+, a statistically non-signiﬁcant value
was found for MTX on this comparison (F= 0.114
p= 0.738), while still a statistically highly signiﬁcant difference
was found between the two groups (F= 253.168, p< 0.001).
3.3. Comparison between active and inactive RA patients and
controls as regards folds of increase of CD4CD25 cell subsets
Increase of CD4+CD25+FoxP3 from 35.10 ± 5.33 in con-
trols to 107.05 ± 7.74 in RRA and 139.95 ± 5.17 in ARA
being 3-folds in the RRA group and 4-folds in the ARA group.T regulatory cell number.
Mean ± SD ANOVA
1402.10 ± 29.68 F= 2515.94
p< 0.001*1369.45 ± 22.18
917.80 ± 18.58
276.25 ± 7.66 F= 2728.518
p< 0.001*260.80 ± 7.33
132.35 ± 4.97
19.70 ± 0.57 F= 536.03
p< 0.001*19.04 ± 0.53
14.42 ± 0.56
136.30 ± 3.28 F= 553.13
p< 0.001*153.25 ± 6.29
97.25 ± 6.25
139.95 ± 5.17 F= 1499.75
p< 0.001*107.05 ± 7.74
35.10 ± 5.33
49.34 ± 0.72 F= 414.84
p< 0.001*58.78 ± 2.46
73.48 ± 3.84
thritis, CD = cluster differentiation, Relative %= percentage of
Figure 2 Flow cytometric analysis of CD4+CD25+ T Cells in HC group (a) RRA group (b) and in ARA group (c) HC = healthy
control, ARA= active rheumatoid arthritis, RRA= remission rheumatoid arthritis.
Figure 3 Examples of ﬂow cytometric results of FoxP3+ T cells in (a) HC group (b) RRA group (c) ARA group. HC = healthy control,
ARA= active rheumatoid arthritis, RRA= remission rheumatoid arthritis.
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Table 3 Correlations between CD4+CD25+FoxP3+ T cells
and disease activity and various studied variables in RA
patients.
Variables CD4+CD25+FoxP3+
R p
Age (years) 0.084 0.606
DD (years) 0.196 0.225
DAS28 0.861 <0.001*
TJC 0.764 <0.001*
SJC 0.796 <0.001*
ESR (mm/hour) 0.759 <0.001*
CRP (mg/dl) 0.753 <0.001*
PGH 0.757 <0.001*
DD= disease duration, DAS = disease activity score,
TJC = tender joint count, SJC = swollen joint count,
ESR= erythrocyte sedimentation rate, CRP = C reactive protein,
PGH= patient global health.
Table 4 Correlations between T cells and disease activity in
RA patients.
T cells (cell number/ll blood) DAS28
r p
CD4+ 0.542 <0.001*
CD4+CD25+ 0.762 <0.001*
CD4+CD25+/CD4+ 0.559 <0.001*
CD4+CD25+FoxP3+ -0.861 <0.001*
CD4+CD25+FoxP3 0.945 <0.001*
Relative % 0.948 <0.001*
DAS = disease activity score, CD= cluster differentiation, Rela-
tive%= percentage of CD4+CD25+FoxP3+ out of
CD4+CD25+ T cells.
190 N. Abaza et al.Increase of CD4+CD25+FoxP3+ from 97.25 ± 6.25 in
control group to 153.25 ± 6.29 in RRA and 136.30 ± 3.28
in ARA being 1.6-folds in RRA and 1.5-folds in ARA.
Thus the ratio of FoxP3/FoxP3+ cells is altered from 1:3
in the control group to 2:3 in the RA group and 1:1 in ARA.
3.4. Correlations between CD4+CD25+FoxP3+ T cells and
disease activity and various studied variables in RA patients
Correlation studies (Table 3) between CD4+CD25+FoxP3+
T cells and clinical data of RA patients showed a negative sta-
tistically highly signiﬁcant correlation (p< 0.001) between
CD4+CD25+FoxP3+ and DAS28 (r= 0.861) (Fig. 4a),
TJC (r= 0.764), SJC (r= 0.796) and PGH
(r= 0.757). As regards laboratory data, a negative highly
signiﬁcant correlation between CD4+CD25+FoxP3+ and
ESR and CRP was found (r= 0.759 and 0.753, respec-
tively). On the other hand there was non-signiﬁcant correla-
tions between CD4+CD25+FoxP3+ and both age and
disease duration.
3.5. Correlations between CD4+CD25+FoxP3+ and therapy
A negative correlation of statistically high signiﬁcance was
foundbetweenCD4+CD25+FoxP3+andMTXdose inRApa-
tients (r= 0.596, p< 0.001). On further eliminating the effect
of this correlation and studying partial correlation betweenr=-0.861   p-value<0.001*
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Figure 4 Correlation between DAS28 and (a) CD4+CD25+FoxP3+CD4+CD25+FoxP3+ andDAS28 there was still a negative sta-
tistically highly signiﬁcant correlation (r= 0.84, p< 0.001).
3.6. Correlations between various T cell subsets and DAS28
See Table 4.
4. Discussion
Despite the presence of an increase in immunoregulatory cells
in RA, chronic inﬂammation persists and activity recurs. This
ﬁnding has been intriguing rheumatologist and immunologist
trying to justify the presence of activity daring this quarterback
of cells usually aiming to ﬁght inﬂammatory process.
The main problem hindering the study of Tregs is the lack
of a single marker that deﬁnes all cells with regulatory activity.
CD4+CD25+ T cells have been identiﬁed as the best-charac-
terized and apparently most important Treg cell population
[27]. The forkhead box P3 (FoxP3) transcription factor is
now considered the most speciﬁc marker, as it is essential for
both Treg cell development and function [28].
Over-expression of FoxP3 by in vitro transfection induces T
cells to exert a complete or partial suppressive activity [29]. On
the contrary, decreased FoxP3 expression enhances autoim-
mune responses by subverting the suppressive function of Treg
cells and converting Treg cells into effector cells [3].
In this observational cross-sectional study, RA patients
showed higher levels of CD4+CD25+ Tregs in the peripheral
blood as compared to healthy controls. This is in accordance
with Han et al., 2008 who studied CD4+CD25+ T cell numbersr=0.945   p-value<0.001*
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Deﬁcient or abundant but unable to ﬁght? Estimation of circulating FoxP3+ T regulatory cells in RA 191in 99RApatients and 44 control subjects and demonstrated it to
be higher in RA patients [11]. They further questioned the para-
dox that since a main purpose of CD4+CD25+ Treg cells is to
control autoimmunity disease, whether this increased number
in the peripheral blood is present but unable to ameliorate dis-
ease activity or present in order to ameliorate it. Also in consis-
tency with VanAmelsfort et al., who stated the same ﬁnding but
viewed it as a trial to suppress the disease [13].
Our work found that RA patients showed higher levels of
PB CD4+CD25+FoxP3+ cells as compared to HC. This is
in accordance with Ryder et al., 2010 who found FoxP3
expression to be higher in RA and further studied CTLA4 to
ﬁnd no concomitant increase indicating that the Tregs were
not functioning in an optimal fashion despite of their increased
number [30]. Our observation is also concomitant with a pre-
vious study which stated that both CD4+CD25+ T cell sub-
types (those expressing FoxP3 and those not expressing it)
contributed to the total increase of these cells in RA compared
to HC but clarifying that though CD4+CD25+FoxP3+ cells
were increased the increase of CD4+CD25+FoxP3 cells
was even more as compared to HC [11]. On the other hand, Su-
zuki et al., 2011 demonstrated signiﬁcantly lower FoxP3 levels
in PB upon studying 23 RA patients and 25 SLE comparing
them to 8 HC. They stated that this decreased expression in
RA and SLE may reﬂect Treg cell abnormalities in these auto-
immune diseases [31]. While back in 2007, Lin et al. demon-
strated that FoxP3 expression in RA was of no signiﬁcant
difference in comparison to healthy control subjects [32].
Upon those contradictory ﬁndings: increased, decreased or
no different than HC, the FoxP3 expression stood yet unex-
plained in relation to RA pathogenesis. Hence, our study
was interested to verify in RA patients the FoxP3+ cells’ state
as an absolute number as well as when studied in terms of per-
centage of CD4 T cells and in relation to the opposing force of
FoxP3 as regards the folds of increase of each. Moreover, we
aimed to verify whether this was related to disease activity.
Therefore, in this work the percentage of FoxP3+ cells
among CD4CD25 T cells in PB of RA was compared to
HC: it was found to be signiﬁcantly lower than HC. This ﬁnd-
ing is suggestive of weakened suppressive response of Tregs in
RA in comparison to HC: although the FoxP3+ cells were
found to be increased as an absolute number compared to
HC, their percentage out of the CD4CD25 T cell population
was not even equal to that of healthy individuals but lower.
This is in accordance with Han et al., 2008 [11]. Also in consis-
tency with Sempere-Ortells et al., 2009 who studied the differ-
ent phenotypes of regulatory T cells in 60 RA patients and 40
HC laying stress on FoxP3 considering it the most speciﬁc
marker for Tregs as it is essential for both their development
and function. They found a signiﬁcant decrease in the percent-
age of this subset in RA compared to HC [33].
As regards the comparison between FoxP3+ and opposing
FoxP3 cells, our study found that both are increased in RA
but with an imbalance favoring FoxP3 increase. The FoxP3+
increase in RA was almost one and a half fold the level in HC
while the FoxP3 increase was about 3-folds the level in HC
and even 4-folds in patients with activity. So both
CD4+CD25+FoxP3+ and CD4+CD25+FoxP3 are in-
creased in RA patients but it is their balance that is more
important; the abundance of FoxP3 cells gave the effector
function the upper hand over the suppressive functionrepresented in FoxP3+ cells that also increased in number
but to the same extent as FoxP3 cells.
In our study, the methotrexate (MTX) dose was found to be
in a negative correlation with the CD4+CD25+FoxP3+ cells,
this is in accordancewithRyder et al., 2010whonoted a negative
correlation between FoxP3 mRNA and the dose of MTX in a
study performed on 50 RA patients and 10 healthy controls
[30]. On the other hand, Oh et al., 2013 studied the effect of var-
ious disease-modifying anti-rheumatic drugs (DMARDS) on
the suppressive function of CD4+CD25+ regulatory T cells
and stated that each DMARD had a different effect on Treg
function demonstrating that sulfasalazine and leﬂunomide
inhibited the anti-proliferative function of Tregs on cocultured
T effector cells (Teffs) and reduced Treg expression of FoxP3
mRNA, whereas MTX and inﬂiximab did not [34]. Our results
could be explained by the hindering effect of MTX on folate as
reported by Kinoshita et al., 2012 that blockade of folate recep-
tor four and treatment with methotrexate, which inhibits folate
metabolic pathways, decreased colonic FoxP3+ Tregs [35]. We
studied the partial correlation between FoxP3+ Tregs and
DAS28, hence eliminatingMTX effect and still the negative cor-
relation between them was strongly revealed. Further studies
especially long term observational ones are needed to specify
the MTX impact on those cells. Better folic acid supplementa-
tion in terms of dose or close interval to MTX administration
might mend the suggested inhibitory effect on FoxP3+ cells if
proven to be true.
In conclusion, CD4+CD25+FoxP3+ and CD4+CD25+
FoxP3 both contribute to the Tregs’ increase in RA. Their ra-
tio might be the key to understand the inability of Tregs to
control disease; the effector function of FoxP3 cells is not
adequately met by a sufﬁcient suppressive function by FoxP3+
cells. This imbalance is related to the presence of RA and to its
activity. Restoring this imbalance by future targeting therapeu-
tics might be of great beneﬁt in RA patients.
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